FDA Grants TXA127 Orphan Drug Status for Rare Genetic Skin Disorder

Recessive Dystrophic Epidermolysis Bullosa is one of the more severe subtypes of epidermolysis bullosa
Recessive Dystrophic Epidermolysis Bullosa is one of the more severe subtypes of epidermolysis bullosa

The Food and Drug Administration has granted Orphan Drug designation to TXA127 (Tarix Orphan) for the potential treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder.

RDEB, one of the more severe subtypes of epidermolysis bullosa, is characterized by extremely fragile skin and mucosa, along with recurrent blister formation and painful sores that result from minor mechanical friction or trauma. Patients with severe form of RDEB often compare the sores to third-degree burns. 

Related Articles

Tarix Orphan is in collaboration with DEBRA Austria for the clinical development of TXA127 for RDEB. The company is also investigating the drug for other genetic diseases including duchenne muscular dystrophy (DMD).

TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide angiotensin (1-7).

For more information visit TarixOrphan.com.

Loading links....